Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (DE:8BT)
FRANKFURT:8BT
RESEARCH TOOLSreports
Total Valuation
BriaCell Therapeutics has a market cap or net worth of C$16.56M. The enterprise value is €22.37M.
Market CapC$16.56M
Enterprise Value€22.37M
Share Statistics
BriaCell Therapeutics has 44,204,163 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,204,163
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BriaCell Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count17
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of BriaCell Therapeutics is ―. BriaCell Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, BriaCell Therapeutics had revenue of ― and earned -4.53M in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income-33.33M
Pretax Income―
Net Income-4.53M
EBITDA-4.59M
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
BriaCell Therapeutics pays an annual dividend of €0.06, resulting in a dividend yield of ―
Dividend Per Share€0.06
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change-86.83%
50-Day Moving Average7.89
200-Day Moving Average12.23
Relative Strength Index (RSI)45.61
Average Volume (3m)350.00
Important Dates
BriaCell Therapeutics upcoming earnings date is Mar 27, 2025, TBA Not Confirmed.
Last Earnings DateDec 16, 2024
Next Earnings DateMar 27, 2025
Ex-Dividend DateSep 05, 2023
Financial Position
BriaCell Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, BriaCell Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
BriaCell Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
BriaCell Therapeutics has ― in cash and marketable securities with 150.62K in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt150.62K
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for BriaCell Therapeutics is C$14.34, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$14.34
Price Target Upside4844.66% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―